

Anti-d immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 250 µg in single-dose vial Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies Rh incompatibility reaction

Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IM: 150 IU per mL in vial Parenteral > Locoregional injections > Other: 150 IU per mL in vial	Rabies

Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IM: 500 IU in vial	Tetanus

C1 esterase inhibitor

Section	Indications
Plasma-derived medicines Parenteral > General injections > IV: 500 IU in vial powder for injection	Hereditary angioedema

Coagulation factor IX

Section	Indications
Blood coagulation factors Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B

Coagulation factor IX complex

Section	Indications
Blood coagulation factors	Therapeutic equivalent to coagulation factor IX for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX for Haemophilia B

Coagulation factor VIII

Section

Blood coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection;
250 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

Haemophilia A

Cryoprecipitate (not pathogen-reduced)

Section

Blood and blood components

Indications

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Haemophilia A

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Von Willebrand disease

Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for

Obstetric haemorrhage

Cryoprecipitate (pathogen-reduced)

Section

Blood and blood components

Injection: frozen liquid in bag or lyophilized powder in vial containing:

> 50 IU Factor VIII

> 100 IU vWF

> 140 mg clottable fibrinogen per unit

Indications

Haemophilia A

Coagulation defects, purpura or other haemorrhagic or related conditions

Von Willebrand disease

Obstetric haemorrhage

Dextran 40

Section

Plasma substitutes

.

Indications

Hypovolaemia

Dextran 70

Section

Plasma substitutes

Parenteral > General injections > IV: 6% injectable solution

Indications

Hypovolaemia

Fresh-frozen plasma

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Normal immunoglobulin

Section

Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

Primary immunodeficiencies

Mucocutaneous lymph node syndrome

Langerhans cell histiocytosis

Platelets

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Polygeline

Section

Plasma substitutes

Parenteral > General injections > IV: 3.5% injectable solution

Parenteral > General injections > IV: 3.5% in solution

Indications

Therapeutic equivalent to dextran 70 for

Hypovolaemia

Hypovolaemia

Red blood cells

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis

Whole blood

Section

Blood and blood components

Parenteral > General injections > IV:

Indications

Blood transfusion without reported diagnosis